DelNova: Addressing complications from Botox (217)

Episode 17 • May 24, 2022 • 00:19:03
DelNova: Addressing complications from Botox (217)
Innovation4Alpha
DelNova: Addressing complications from Botox (217)

May 24 2022 | 00:19:03

/

Show Notes

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. 

Other Episodes

Episode 24

October 13, 2021 • 00:33:25
Episode Cover

Startup Profile: Embrace Prevention Care (024)

Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that...

Listen

Episode 1

July 17, 2024 • 00:31:16
Episode Cover

Lessons Learned as a Surgeon & Fund Investor

In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA...

Listen

Episode 29

December 19, 2021 • 00:19:16
Episode Cover

Transverse Medical (029)

TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex...

Listen